A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Participants received two doses of the FLU-Q-PAN H7N9 Formulation 1 vaccine by intramuscular injection in the non-dominant arm.

Participants received two doses of the FLU-Q-PAN H7N9 Formulation 2 vaccine by intramuscular injection in the non-dominant arm.

Participants received two doses of the FLU-Q-PAN H7N9 Formulation 3 vaccine by intramuscular injection in the non-dominant arm.

Participants received two doses of the AS03B adjuvant by intramuscular injection in the non-dominant arm.

Participants received two doses of the AS03A adjuvant by intramuscular injection in the non-dominant arm.

Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.